SCHEMBL5541006

SCHEMBL5541006

C[C@H](O)CNC(=O)c1c(O)c2ncc(Cc3ccc(F)cc3)cc2[nH]c1=O

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.47
KDM5A P29375 3/20 0.39
PARP1 P09874 1/20 0.39
GSK3B P49841 1/20 0.38
MEN1 O00255 7/20 0.38
KMT2A Q03164 7/20 0.38
KDM4E B2RXH2 3/20 0.38
RXFP1 Q9HBX9 1/20 0.37
CNR2 P34972 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
NLRP3 Q96P20 1/20 0.35
PKM P14618 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
MITF O75030 1/20 0.35
HTT P42858 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
USP2 O75604 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5546882 1.00 TDP1 (0.47) TDP1KDM5APARP1GSK3BMEN1
SCHEMBL5543155 1.00 TDP1 (0.47) TDP1KDM5APARP1GSK3BMEN1
SCHEMBL5547305 0.93 TDP1 (0.48) TDP1KDM5APARP1GSK3BMEN1
SCHEMBL14511037 0.88 TDP1 (0.46) TDP1KDM5AGSK3BMEN1KMT2A
SCHEMBL5548065 0.87 KDM5A (0.49) TDP1KDM5APARP1GSK3BMEN1
SCHEMBL15163541 0.87 TDP1 (0.48) TDP1KDM5AGSK3BMEN1KMT2A
SCHEMBL5547382 0.86 TDP1 (0.47) TDP1KDM5AGSK3BMEN1KMT2A
SCHEMBL15163542 0.86 TDP1 (0.48) TDP1KDM5AGSK3BMEN1KMT2A
SCHEMBL5538646 0.85 TDP1 (0.47) TDP1KDM5AGSK3BMEN1KMT2A
SCHEMBL5546578 0.85 TDP1 (0.43) TDP1KDM5AGSK3BMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 EP disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 TDP1 801/4885KDM5A 2056/4885PARP1 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.